… available drugs for Parkinson disease address dopaminergic loss and relieve symptoms.
However, their adverse effects can be limiting and they do not address disease progression. …

… of parkinsonism is idiopathic Parkinson’s disease (PD), first described by James Parkinson,
… Parkinson described the major symptoms of the disease that would later bear his name. For …

… place of medical treatment for Parkinson's disease. Unfortunately… clinical diagnosis of
Parkinson's disease have been outlined … patient has idiopathic Parkinson's disease with significant …

… Decision pathway for the treatment of advancing and complex Parkinson disease. MAO-BI
indicates monoamine oxidase B inhibitor; COMT-I, catechol-O-methyltransferase inhibitor. …

… In young, cognitively intact individuals with Parkinson disease, anticholinergic agents may
… across Parkinson disease stages. With progression, individuals with Parkinson disease will …

… Parkinson disease (PD) has been described as one of the most complex syndromes
encountered in clinical medicine. Long-term treatment with dopaminergic agents, the mainstay of …

The cardinal characteristics of Parkinson disease (PD) include resting tremor, rigidity, and
bradykinesia… addresses the treatment of motor and nonmotor symptoms of Parkinson disease. …

… & Contemporary medical management is heavily reliant on pharmacologic interventions,
although surgical treatments (eg, deep brain stimulation) also play a role. Exercise interven…

… Parkinson disease results in considerable morbidity and financial strain. The cost of Parkinson
disease in terms of … and nonpharmacologic treatment of early-stage Parkinson disease. …

… Older age and male sex are the most established risk factors for Parkinson disease (PD). …
according to the revised MDS-Unified Parkinson's Disease Rating Scale (UPDRS) to …